+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

W

Actively Recruiting

This research aims to improve how appendicitis, a common emergency surgery condition, is managed worldwide by studying different emergency care systems. Appendicitis requires quick diagnosis and treatment to avoid complications. Using appendicitis as a marker, the study looks at access, quality, and efficiency across hospitals in various countries, including low- and middle-income regions, to find ways to enhance emergency surgical care. The study collects data from about 500 hospitals globally between February and May 2025, focusing on patients undergoing appendicectomy using any surgical method, including open, laparoscopic, or robotic approaches. Hospitals will record information for consecutive patients over 14-day periods. The study includes two sub-studies one on sustainability and waste management in operating rooms and another on the financial impact of surgery on patients, especially in resource-limited settings. Participants will have their care observed through routine health records without extra follow-up visits. Researchers will measure key factors such as time from symptoms to surgical assessment, rates of minimally invasive surgery, complications within 30 days, and hospital stay length. This data will help identify gaps and guide improvements in emergency surgical care worldwide, aiming to make treatment safer, faster, and more affordable.

All AgesAll Genders
7 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety and immune response of different dosing schedules and reduced doses of the RTS,SAS01E malaria vaccine in healthy children aged 5 to 60 months living in areas where malaria is common. This Phase 2a open-label randomized study aims to find the best vaccination regimen to protect young children against malaria, a serious infectious disease. The study is sponsored by GlaxoSmithKline and targets healthy children who have completed routine immunizations. Participants are randomly assigned to receive three doses of the RTS,SAS01E vaccine on one of three schedules Day 1, Month 1, and Month 2 Day 1, Month 1, and Month 7 or Day 1, Month 2, and Month 7. The vaccine is given as an injection into the muscle. The study follows participants for up to 19 months to compare immune responses and safety across these different dosing schedules. During the study, children will have blood tests at multiple time points to measure antibodies against malaria and hepatitis B, along with monitoring for any side effects following vaccination. Researchers will track any adverse events, including serious ones, for up to 19 months after the first dose. Parents or guardians will complete diaries and attend follow-up visits to help monitor health and vaccine effects throughout the study period.

Age: 5Months - 60MonthsAll GendersPhase 2
2 locations
E

Actively Recruiting

Pregnancy is a crucial time to assess cardiovascular health and find ways to lower the risk of heart disease for both mothers and their children. Researchers are exploring the use of the American Heart Associations Lifes Essential 8 as a tool to evaluate cardiovascular health in pregnant women. This study aims to understand how well this indicator applies during pregnancy and to set suitable cardiovascular health standards for this group. Participants will be involved in an observational study that includes completing questionnaire surveys, clinical follow-ups, and specimen collection. The focus is on gathering data about cardiovascular health during pregnancy without administering any treatments. The study follows pregnant women from early pregnancy through delivery. During the study, participants will undergo routine prenatal examinations and provide clinical data to help researchers track maternal and neonatal outcomes through delivery, up to 42 weeks. The research team will assess how cardiovascular health relates to pregnancy results, using questionnaires and collected specimens. This study helps improve understanding of heart health during pregnancy and its impact on both mother and baby.

Age: 20Years - 49YearsFEMALE
3 locations
S

Actively Recruiting

This research aims to find out if wearable sensors can help detect early signs of health problems after major surgery. The study focuses on surgical patients who might become critically ill after their operations. It evaluates if continuous monitoring of vital signs like heart rate and oxygen levels using wearable devices can identify patient deterioration sooner than standard care. The study is observational and involves multiple countries including Benin, Ghana, Guatemala, India, Mexico, Nigeria, Rwanda, and the United Kingdom. Participants will wear wireless sensors on their chest and fingers before, during, and after surgery for up to 10 days. These sensors record vital signs continuously but do not affect patient care, as clinical teams will not access the data during the study. The first two stages of the study involved testing device usability with healthcare workers, while this third stage collects real-time sensor and clinical event data to explore links between physiological changes and patient complications. During the study, participants will have their vital signs monitored with wearable devices while also receiving standard clinical observations. Researchers will collect cardiovascular, respiratory, and temperature data alongside routine care information and clinical events. They will follow patients for 10 days of monitoring plus an additional 30-day follow-up to observe complications. The goal is to gather data to help design future algorithms for early detection of postoperative problems without changing current treatment practices.

Age: 18Years +All Genders
17 locations
E

Actively Recruiting

Cervical cancer disproportionately affects women living with HIV WLWH in low- and middle-income countries, including Rwanda, where WLWH have a sixfold higher risk compared to the general population. Researchers are evaluating a new approach using thermal ablation TA with two probes to treat cervical precancerous lesions among WLWH. This feasibility study aims to provide evidence to improve treatment outcomes and support Rwandas goal to eliminate cervical cancer by 2027. Participants who test positive for high-risk HPV or visual inspection with acetic acid undergo further clinical exams, including biopsies and digital imaging. Eligible women with a type 1 transformation zone will be randomly assigned to receive TA treatment either with one probe or with two probes. Follow-up occurs at six months to assess persistent HPV and treatment effects. Women not eligible for TA will be referred for local care. During the study, participants complete screening tests and clinical exams at enrollment and return for a six-month follow-up visit with HPV testing, biopsies, and visual cervical assessment. Researchers will measure the proportion of women with persistent HPV at six months to evaluate treatment success. The study, supported by Fred Hutchinson Cancer Center, lasts from October 2026 to May 2028.

Age: 25Years - 49YearsFEMALEPhase Not Applicable
1 location
E

Actively Recruiting

This research aims to understand how national medical oxygen strategies work and achieve impact at both national and local levels across different countries. It focuses on health systems and policy contexts in six countries involved in the Medical Oxygen Implementation program. The study seeks to involve policymakers, implementers, and medical oxygen users to identify challenges and find potential solutions to improve access to medical oxygen. Researchers also aim to generate new data and draw lessons that can inform national and global policy and practice. The study uses a mixed-methods design with three embedded parts stakeholder analysis, policy-implementation gap analysis, and comparative country case studies. It involves interviews with key informants from government, NGOs, professional associations, private sector, and civil society. The study is conducted in six countries and will be adapted to each context through ongoing collaboration with stakeholders. The research will run for four years and includes annual meetings to refine study topics and methods. Participants will take part in in-depth interviews focusing on national medical oxygen strategies over the four-year study period. Researchers will review policies, analyze program data, and compare findings across countries. The study will monitor how strategies are translated into action and their effects on oxygen service coverage. This involves collecting qualitative and quantitative data to better understand the implementation and challenges of medical oxygen programs within different health systems.

Age: 18Years +All Genders
6 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating Mpox, a disease with rising cases in Central and East Africa, caused by two virus strains with different characteristics and spread patterns. The study aims to develop new immune tests to estimate how many people have been exposed to Mpox or vaccinated, helping to prioritize vaccine use in affected communities. This outbreak is considered a public health emergency due to increasing cases and deaths, especially with limited testing in some regions. Participants are grouped by their exposure status those at risk but without symptoms, those recovered from Mpox or vaccinated, and those with no known exposure. The study uses diagnostic tests including an Mpox-specific antibody ELISA and a dried blood spot lateral flow assay to detect immune responses. All participants undergo the same testing procedures to assess their exposure or immunity status. During the study visit, participants provide biological samples for testing and complete surveys about their views on outbreak studies, immune diagnostic tools, and vaccine logistics. Researchers will measure Mpox-specific antibodies and evaluate rapid test accuracy. The study will also gather perspectives from healthcare workers and the public to support future vaccine strategies. The total participation involves sampling and questionnaires conducted on the first day.

Age: 5Years - 80YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination of anti-malarial drugs in children aged 2 to under 12 years with uncomplicated Plasmodium falciparum malaria. This phase 2 platform study compares a single oral dose of up to three anti-malarial agents given together to the standard treatment known as Coartem. The study aims to better understand how these treatments work and their safety profiles in this young population. Participants are randomly assigned to one of two groups one receiving an oral combination of KLU156 with KAE609 alongside a light meal, and the other receiving the standard of care, Artemether plus lumefantrine, given orally according to the usual guidelines. This open-label, two-arm study monitors each treatment groups response to therapy. Throughout the study, participants undergo evaluations including parasite clearance times and blood tests to measure drug levels over the first week, with the main outcome assessed on day 29 using PCR to confirm clinical and parasitological response. Safety and tolerability are also closely monitored, and the total duration of participation extends up to 29 days after treatment initiation to assess treatment outcomes comprehensively.

Age: 2Years - 12YearsAll GendersPhase 2
13 locations
E

Actively Recruiting

Researchers are evaluating the accuracy of an AI-enabled ultrasound tool designed to estimate fetal weight in pregnant individuals. This prospective diagnostic study aims to compare AI-generated fetal weight estimates with specialist-performed fetal biometry and actual birth weights to assess the tools performance. The study involves 1,000 pregnant participants expected to deliver within one week of the study procedure, focusing on pregnancies between 24 and 42 weeks of gestation. Participants will undergo two ultrasound assessments during a single visit within one week of delivery. The first consists of standardized sweeps of the gravid abdomen captured as cineloop videos, performed by both specialist and nonspecialist users, which are then analyzed by a deep-learning AI diagnostic tool to estimate fetal weight. The second assessment involves specialist-performed fetal biometry measurements. These two methods will be compared to actual birth weights to evaluate diagnostic accuracy. During the study visit, participants receive the ultrasound procedures as part of the research. Researchers will measure the difference in Mean Absolute Percent Error MAPE between AI estimates and actual birth weights, along with the proportion of estimates within 10% of actual birth weight. The study is conducted by the University of North Carolina, Chapel Hill, and involves no masking or blinding. The total participation involves a single visit shortly before delivery, with data collection focused on comparing diagnostic methods.

Age: 18Years +FEMALEPhase Not Applicable
6 locations
A

Actively Recruiting

Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.

Age: 18Years +All GendersPhase 3
52 locations

1-10 of 12

1